Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > February 2, 2024
Daily News
February 2, 2024
- Physician Meals Costs, Seminar Expenses Newly Subject to Disclosure under Clinical Trials Act from April
February 2, 2024
- Chugai’s 2023 Earnings Slip as Ronapreve Wanes, but Sales Still Top 1 Trillion Yen
February 2, 2024
- Chugai to Make Singapore Unit a Permanent Drug Discovery Research Base
February 2, 2024
- Takeda’s April-December Sales Up 4.6%, but Flat at CER
February 2, 2024
- Takeda Bags Global Rights to Protagonist’s Rare Hematology Asset
February 2, 2024
- Annual Drug Price Revisions Based on 4-Minister Agreement: Japan PM
February 2, 2024
- Milano Furuta to Take Over as CFO of Takeda in April
February 2, 2024
- Cheplapharm Takes Over Xeloda from Chugai in Japan
February 2, 2024
- Cefiderocol Approved for Use in China’s Special Medical Tourism Zone: Shionogi
February 2, 2024
- Shionogi Sees 60% Ramp-Up in Medicon Output in FY2023
February 2, 2024
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…